Valuation: Nanobiotix

Market Cap 1.67B 1.91B 1.54B 1.42B 2.68B 184B 2.74B 18.44B 7.25B 90.21B 7.18B 7.03B 311B P/E 2026 *
-80.2x
P/E 2027 * -139x
Enterprise Value 1.72B 1.97B 1.58B 1.46B 2.75B 189B 2.81B 18.94B 7.45B 92.7B 7.38B 7.22B 319B EV / Sales 2026 *
39.2x
EV / Sales 2027 * 32.1x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-1.55%
1 week-7.31%
Current month+2.68%
1 month+8.42%
3 months+14.84%
6 months+78.35%
Current year+69.03%
1 week 30.5
Extreme 30.5
37.46
1 month 28.94
Extreme 28.94
37.46
Current year 16.66
Extreme 16.66
47.66
1 year 4.15
Extreme 4.15
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
2/20/26 Buy

Chairman

1,100 0.0023%
2/13/26 Buy

Chairman

1,500 0.0031%
12/3/25 Sell

Chief Executive Officer

295,000 0.6153%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-7.31%+626.79%+414.20% 1.91B
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average -0.10%-0.71%+128.29%+133.52% 24.55B
Weighted average by Cap. -0.07%-0.24%+84.01%+125.74%

Financials

2026 *2027 *
Net sales 43.85M 50.18M 40.47M 37.3M 70.3M 4.83B 71.86M 484M 190M 2.37B 188M 184M 8.15B 54.52M 62.39M 50.31M 46.38M 87.41M 6.01B 89.35M 601M 237M 2.94B 234M 229M 10.13B
Net income -7.65M -8.75M -7.05M -6.5M -12.26M -842M -12.53M -84.32M -33.17M -413M -32.85M -32.13M -1.42B 6.46M 7.4M 5.97M 5.5M 10.36M 712M 10.59M 71.3M 28.04M 349M 27.78M 27.17M 1.2B
Net Debt 46M 52.64M 42.45M 39.13M 73.74M 5.07B 75.38M 507M 200M 2.48B 198M 193M 8.55B 76.4M 87.43M 70.5M 64.99M 122M 8.42B 125M 843M 331M 4.12B 328M 321M 14.2B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-07-17 €32.96 -1.55% 160,134
26-07-16 €33.48 -3.68% 120,384
26-07-15 €34.76 -3.98% 147,588
26-07-14 €36.20 +3.61% 141,510
26-07-13 €34.94 -1.74% 101,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
32.96EUR
Average target price
52.20EUR
Spread / Average Target
+58.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock